Edesa Biotech Reports Fiscal Year 2023 Results

December 15, 2023 4:10 PM

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business.During the year, Edesa reported favorable results from two clinical studies and achieved multiple regulatory and operational...

Read more

enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium

December 14, 2023 11:30 AM

- Interviews with patients from the VenoValve® pivotal study- Materials now available on the Company's websiteIRVINE, CA / ACCESSWIRE / December 14, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it has posted Company highlights and materials from the recently held 50th Annual VEITH Symposium on the enVVeno website....

Read more

Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview

December 14, 2023 10:00 AM

Company focused on advancing novel personalized cancer vaccines to overcome tumor resistance to immunotherapies like checkpoint inhibitors; and first-in-class bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs) to modulate their immunosuppressive effects on the tumor microenvironmentCompany on track to initiate pivotal Phase 3 study of lead program, IFx-2.0, in Merkel Cell Carcinoma (MCC) in 2024...

Read more

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

December 14, 2023 8:15 AM

Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity ReductionPF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its most recent study has...

Read more

Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)

December 14, 2023 7:00 AM

Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences' cannabinoid-based medicine for the treatment of Parkinson's disease.LAS VEGAS, NV / ACCESSWIRE / December 14, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, will be featured on Worldwide Business with kathy ireland® on Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business...

Read more

Moolec Science Presents First Quarter Fiscal Year 2024 Business Update

December 14, 2023 6:00 AM

LUXEMBOURG / ACCESSWIRE / December 14, 2023 / Moolec Science SA (NASDAQ:MLEC), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the first quarter of Fiscal Year 2024 ended September 30, 2023.The main highlights of Moolec's business update are as follows:GLASO: Moolec harvested 35 hectares with a yield of 1.8 tons per hectare....

Read more

MindMics, Inc. Honored with Two CES(R) 2024 Innovation Honoree Awards

December 14, 2023 3:00 AM

CAMBRIDGE, MA / ACCESSWIRE / December 14, 2023 / MindMics, the inventor of infrasonic sound-based technology for in-ear earphones and hearables, today announced that it has been named a CES® 2024 Innovation Awards Honoree in the digital health and wearables technology categories for the MindMics Heart Health System. This year's CES Innovation Awards program received a record number of over 3000 submissions. The announcement was made ahead of CES...

Read more

AppYea Provides Year-End Letter to Shareholders Recapping Key Achievements and Sharing Outlook for 2024

December 13, 2023 6:20 AM

GAN YAVNE, ISRAEL / ACCESSWIRE / December 13, 2023 / AppYea Inc. (OTCQB:APYP), focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, today provided the following letter to shareholder from the Company's CEO, Adi Shemer: To our valued shareholders,I am thrilled to share the remarkable strides our company has made throughout the past year. This period has undeniably marked a pivotal turning point...

Read more

Disrupting T-Cell AI Stack by QuBind.com Enables - AI-Accelerated T-Cell Therapy Discovery and Next Gen Liquid Biopsies

December 12, 2023 11:20 AM

NEW YORK, NY / ACCESSWIRE / December 12, 2023 / QuBind, a startup at the forefront of T-cell therapy innovation, announces a significant development in immunotherapy with its AI-integrated platform. This platform enhances the accuracy and safety of T-cell therapies, addressing key challenges in the field. QuBind's approach utilizes a novel AI stack to analyze immune system responses, facilitating the discovery of effective treatments and...

Read more

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

December 12, 2023 10:00 AM

Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approvalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the completion of a Human Factors Study, whose objective was to assess the technology component developed...

Read more

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider

December 12, 2023 9:15 AM

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces its partnership with Idea Evolver (IE), a Technology platform for Rx-to-OTC switches and digital...

Read more

Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.

December 12, 2023 9:00 AM

MIAMI, FL / ACCESSWIRE / December 12, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of treatments for neurological diseases, is thrilled to announce the appointment of Dr. Neilank K. Jha as its new Executive Chairman and Chief Executive Officer.Dr. Jha is recognized for his extensive experience and wealth...

Read more

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

December 11, 2023 8:01 AM

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single doseTH104 was well tolerated with no unexpected treatment-emergent adverse events comparable to previous phase 1 studiesCompany funded into early 2025 and expects bridging PK data in the US and Phase 2a results for chronic pruritus in primary biliary cholangitis (PBC) in 2024BRIDGEWATER, NJ /...

Read more

Bionoid Pharma Inc. Provides Update on Binding Letter of Intent to Acquire Global Alerts Corp.

December 8, 2023 7:00 AM

"Paving the Way for a Safer World Through Advanced Emergency Communications"TORONTO, ON / ACCESSWIRE / December 8, 2023 / Bionoid Pharma, Inc. ("BINP" or the "Company") (OTC PINK:BINP) is pleased to announce a significant development in its ongoing partnership negotiations with Global Alerts Corp. ("Global Alerts"). After successfully extending the effective period of the non-binding Letter of Intent ("LOI") and its exclusivity provisions,...

Read more

FREEDOM HOLDINGS (FHLD) SHAREHOLDER UPDATE; 15c211 Nears Final Approval from FINRA 

December 8, 2023 6:00 AM

CHATSWORTH, CA / ACCESSWIRE / December 8, 2023 / Freedom Holdings, Inc. aka Freedom Acquisition Corp. (OTC PINK:FHLD) ("FHLD" or the "Company") is pleased to announce following Company Update: Freedom Holdings waiting on 15c211 final approval from FINRA.This past summer, Freedom Holdings had worked diligently with a Glendale Securities over the past several months to seek FINRA approval of its 15C-211. We expect having that approval any day now....

Read more

FluoGuide Raises SEK 12 million through Exercise of Warrants

December 8, 2023 4:15 AM

KØBENHAVN, DK / ACCESSWIRE / December 08, 2023 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a pioneer in the cutting-edge field of precision cancer surgery, today announced the status of the exercised warrants, issued in connection with the directed share issue in July this year, raising SEK 12 million. On August 28, 2023, a total of 211,389 warrants were issued as part of the directed share...

Read more

Vaso Corporation, a Diversified Medical Technology Company Currently Trading on the OTCQX Market, to List on Nasdaq via SPAC Merger

December 7, 2023 5:00 PM

Business Combination with Achari Ventures Holdings Corp. I is Expected to Be Completed in First Quarter of 2024Merger with Achari Ventures Holdings Corp. I (NASDAQ:AVHI) expected to improve capital market access for existing and prospective investors of Vaso Corporation (OTCQX:VASO).The transaction values Vaso at a pro forma equity value of approximately $176 million at $10 per share.Upon closing of the transaction, existing Vaso shareholders...

Read more

Lexaria's Investigational New Drug Application Filing Update

December 7, 2023 9:20 AM

KELOWNA, BC / ACCESSWIRE / December 7, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.As...

Read more

Moolec Science to Host First Quarter Fiscal Year 2024 Business Update Conference Call

December 7, 2023 8:00 AM

LUXEMBOURG / ACCESSWIRE / December 7, 2023 / Moolec Science SA (NASDAQ:MLEC)("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the First Quarter Fiscal Year 2024 on Thursday, December 14, 2023, before the market opens. MLEC Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer...

Read more

Canopus Biopharma Inc. Dba Blue Heaven Coffee Inc. Announces and Secures Financial Payment Processing Provider Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) with a focus on Nayax's CoinBridge Enablement for the Processing of Bitcoin (BTC) and Other Virtual Assets in Unattended Retail Framework

December 7, 2023 7:00 AM

LAS VEGAS, NV / ACCESSWIRE / December 7, 2023 / Canopus Biopharma Inc. (OTC PINK:CBIA) Dba Blue Heaven Coffee Inc. (BHC) is pleased to announce its association with internationally recognized global commerce enablement, payments, and loyalty platform Provider Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX). Nayax offers a complete payment solutions platform including localized cashless payment acceptance, management suite, and consumer engagement tools,...

Read more